Analysis and Prospect of the Pharmaceutical Industry Development Trend in China
Kong Fei,Cao Yuan,Xu Ming,Li Haiyan,Qiao Jie
DOI: https://doi.org/10.15302/j-sscae-2023.05.003
2023-01-01
strategic study of chinese Academy of engineering
Abstract:The development of the pharmaceutical industry is the cornerstone for safeguarding people’s lives and health. This study is based on a macro perspective and provides a comprehensive and in-depth comparison of the development trend of the pharmaceutical industry in China and abroad. It is pointed out that the global market size and strategic position of the pharmaceutical industry in various countries are constantly improving. Meanwhile, the development prospect of China’s pharmaceutical industry is broad, and the potential market space is large. On this basis, we further explore the development prospects and driving factors of China’s pharmaceutical industry, including changes in population structure and increased health awareness, increasing global competitive pressure, sustained government investment and support for the pharmaceutical industry, and increase in research and development (R & D) investment by leading enterprises. Moreover, from the perspective of medical practice, we propose the challenges faced by the pharmaceutical industry in five aspects: precision, safety, timeliness, affordability, and policy guarantee. Furthermore, in response to the challenges we face, we propose the following targeted countermeasures: (1) building and maintaining a refined large-populationbased cohort and data platform while providing sustained support; (2) accelerating the R & D and transformation of China’s internationally leading technologies in the pharmaceutical industry to strengthen original innovation and seize the market; (3) promoting the industrialization of pharmaceutical R & D by encouraging industry–education–research integration in the R & D and clinical trials stage, strengthening the evaluation ability in the evaluation stage, and improving guarantee services such as intellectual property protection in the promotion stage of innovative products; (4) improving multi-level medical security channels to strive for more sources of support and reduce the burden of self-payment for patients; and (5) enhancing the full chain of policy protection and implementation efficiency to effectively stimulate the development momentum of the medical industry. This study aims to provide a reference for the subsequent investment, policy formulation, and development decisions of China’s pharmaceutical industry.